Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence

Varicose Veins Clinical Trial

— VANISH-2  

Official title:

A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Varisolve Polidocanol Endovenous Microfoam (PEM) 0.5% and 1% Compared to Vehicle for the Treatment on Saphenofemoral Junction (SFJ) Incompetence "VANISH-2"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01231373
• Other study ID #: VAP.VV016
• Status: Completed
• Phase: Phase 3
• Start date: November 2010
• Est. completion date: August 2014

Study information

• Verified date: April 2021
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the safety and effectiveness of three different concentrations of an investigational drug, Polidocanol Endovenous Microfoam (PEM) compared to vehicle (inactive solution) in treating the symptoms and appearance of varicose veins.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 235
• Est. completion date: August 2014
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Incompetence of SFJ associated with incompetence of the GSV or other major accessory vein

• Ability to comprehend and sign an informed consent document and complete study questionnaires in English

• Ability to record symptoms in accordance with the protocol

• Symptomatic varicose veins

• Visible varicose veins

Exclusion Criteria:

• Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as assessed by CEAP Classification of Venous Disorders).

• Leg obesity impairing the ability to access the vein to be treated and/or to apply post-procedure compression bandaging and stockings

• Ultrasonographic or other evidence of current or previous deep vein thrombosis or occlusion

• Deep vein reflux unless clinically insignificant in comparison to superficial reflux

• Peripheral arterial disease precluding the wearing of post-procedure compression bandaging and stockings

• Reduced mobility

• Major surgery, prolonged hospitalization or pregnancy within 3 months of screening

• Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic insufficiency; serious skin disease/condition that may compromise the ability of the patient to comply with the compression protocol, etc.)

• Known allergic response to polidocanol or heparin, including history of heparin-induced thrombocytopenia, and/or multiple allergic reactions

• Current alcohol or drug abuse

• Pregnant or lactating women

• Women of childbearing potential not using effective contraception

• History of DVT, pulmonary embolism, or stroke

Related Conditions & MeSH terms

• Varicose Veins

Intervention

Drug:
• polidocanol injectable foam, 0.125%
active placebo for blinding
• polidocanol injectable foam, 0.5%
0.5% polidocanol foam injection
• polidocanol injectable foam, 1.0%
1.0% polidocanol foam injection
• Vehicle
injection of vehicle comparator

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Boston Scientific Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score)	The 9 varicose vein symptoms were to be assessed and graded on a 6-point (i.e., 0-5) duration scale and an 11-point (i.e., 0-10) intensity scale, and the patient's level activity for that day was to be assessed and graded on the 6-point (i.e., 0-5) duration scale. The 9 varicose vein symptoms assessed using the e-diary were derived from the first question of the modified Venous Insufficiency Epidemiologic and Economic Study-Quality of Life/Symptoms (VEINES-QOL/Sym) instrument. The VVSymQ is a subset of 5 VEINES QOL/Sym items that have been determined in earlier studies to be most important to patients. The daily VVSymQ score is the sum of the duration scores for these 5 symptoms (scores range from 0 to 25). At Visit 2/baseline, Week 8, scores were calculated.	8 weeks
Secondary	Change From Baseline to 8 Weeks in Appearance as Rated by Patient (PA-V3)	The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this single-item paper questionnaire, the instructions included a diagram fo the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from "Not at all noticeable" (a score of 0) to "Extremely noticeable" (a score of 4).	8 weeks
Secondary	Change From Baseline at 8 Weeks Post-Treatment in IPR-V3 Score--Physician Photographic Review of Appearance	The Independent Photography Review--Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient's visible varicose veins. At baseline and Week 8, standardized digital photographs were taken of the medial view of the patient's target leg, from groin to ankle. An independent photography review panel, consisting of 3 trained, blinded clinicians, evaluated the appearance of the patient's visible varicose veins using the IPR-V3 instrument's 5-point scale (0-4, where 0=none and 4=very severe visible varicose veins).	8 weeks